Find Print
0 Find synonyms

Find synonyms Find exact match

What's new in hematology
Official reprint from UpToDate® ©2017 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
What's new in hematology
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Mar 2017. | This topic last updated: Apr 24, 2017.

The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.


Arsenic trioxide plus ATRA for acute promyelocytic leukemia (March 2017)

Arsenic trioxide (ATO) combined with all-trans retinoic acid (ATRA) can induce complete molecular remissions in acute promyelocytic leukemia (APL) without the use of cytotoxic chemotherapy. In longer-term follow-up of the landmark international study, APL0406, patients with low or intermediate-risk APL (white blood cell <10,000/microL) were evaluated through the consolidation and maintenance phases of therapy [1]. In this analysis, ATO plus ATRA was associated with less toxicity, fewer deaths during induction therapy, and fewer short-term and long-term relapses compared with ATRA plus conventional chemotherapy. We recommend treatment with ATO plus ATRA for patients with low or intermediate-risk APL. (See "Initial treatment of acute promyelocytic leukemia in adults", section on 'Arsenic trioxide plus ATRA'.)

Blinatumomab for relapsed/refractory ALL (March 2017)

For patients with relapsed or refractory lymphoblastic leukemia (ALL), the initial goal of treatment is achievement of complete remission, but such remissions are typically short-lived; cure generally requires allogeneic hematopoietic cell transplantation (HCT). Blinatumomab is a bispecific antibody directed against both CD19 (expressed on the leukemic blast cells) and CD3 on the patient’s own T lymphocytes. In a randomized international trial of approximately 400 patients with relapsed or refractory ALL, blinatumomab resulted in superior overall survival, event-free survival, and response rate compared with state-of-the-art cytarabine-based chemotherapy [2]. Despite substantial toxicities (which are comparable to conventional chemotherapy), we now recommend blinatumomab, rather than chemotherapy, for remission induction prior to allogeneic HCT in relapsed or refractory ALL. (See "Treatment of relapsed or refractory acute lymphoblastic leukemia in adults", section on 'Blinatumomab'.)

2017 European LeukemiaNet (ELN) prognostic stratification scheme for AML (February 2017)

Cytogenetic and molecular features of acute myelogenous leukemia (AML) permit stratification of patients into various prognostic groups. We prefer the classification system recently updated by the European LeukemiaNet (ELN) (table 1) [3]. This revised schema distinguishes three prognostic categories and incorporates data on additional gene mutations (eg, TP53, ASXL1), biallelic mutated CEBPA, the allelic ratio of FLT3-ITD, and effects of specific combinations of such features. These prognostic variables, coupled with the patient's clinical status, often inform key therapeutic decisions regarding management of AML. (See "Prognosis of acute myeloid leukemia", section on 'European LeukemiaNet classification' and "Post-remission therapy for acute myeloid leukemia in younger adults" and "Treatment of relapsed or refractory acute myeloid leukemia".)


Cardiovascular risk in sickle cell trait (March 2017)

Sickle cell trait is a benign carrier state, but concerns have been raised about increased cardiovascular risk factors. Analyses from several large cohorts have now provided reassuring evidence that there are no differences in the risks of diabetes, hypertension, or heart failure in blacks with sickle cell trait compared with the general black population [4,5]. (See "Sickle cell trait", section on 'No increased risk of hypertension, diabetes, or heart failure'.)

Experimental gene therapy for sickle cell disease (March 2017)

The first case report of gene therapy for sickle cell disease (SCD) has been published [6]. The patient was a 13-year-old boy with SCD who had pain despite treatment with hydroxyurea and transfusions. He received an autologous hematopoietic cell transplant (HCT) using his own hematopoietic cells that had been transduced with a vector to express a modified beta globin gene with anti-sickling properties. After HCT, he became free of pain and independent of transfusions and analgesics. Additional studies of this approach are underway. (See "Investigational therapies for sickle cell disease", section on 'Gene therapy'.)

Glycated hemoglobin (A1C) in sickle cell trait (March 2017)

In a retrospective cohort study evaluating glycated hemoglobin (A1C) in African Americans with and without sickle cell trait, A1C was lower at any fasting glucose value in patients with sickle cell trait compared with controls [7]. However, the study is limited by its methodology, as mean glucose levels were estimated on the basis of very few measurements, usually a single fasting glucose level or oral glucose tolerance test. A1C correlates best with mean blood glucose over 8 to 12 weeks, raising the possibility that if measured appropriately with frequent glucose measurements over time (multiple daily measurements or continuous glucose monitoring), mean glucose levels may actually have been different between the study populations, with the putative different A1C levels accurately reflecting these different mean glucose levels. We continue to use A1C as one option to diagnose diabetes in patients with sickle cell trait. (See "Estimation of blood glucose control in diabetes mellitus", section on 'Racial variation'.)

Rapidly progressive acute chest syndrome in sickle cell disease (February 2017)

Acute chest syndrome (ACS) in individuals with sickle cell disease (SCD) encompasses a variety of clinical presentations and severities. A distinct phenotype of ACS has been characterized, referred to as rapidly progressive ACS, in which respiratory failure occurs within 24 hours of initial respiratory symptoms [8]. In a cohort of 97 children and 76 adults with SCD and at least one prior ACS episode, rapidly progressive ACS occurred more commonly in adults than children (21 versus 2 percent). Adults with rapidly progressive ACS were more likely to have multiorgan failure compared with adults without this phenotype. The only laboratory predictor of rapidly progressive ACS was a decline in platelet count on presentation. (See "Evaluation of acute pain in sickle cell disease", section on 'Acute systemic illness, diffuse pain, or both'.)

Crizanlizumab for sickle cell pain episodes (December 2016)

Crizanlizumab is an investigational monoclonal antibody directed against P-selectin, an adhesion molecule that contributes to vasoocclusive pain in individuals with sickle cell disease (SCD). In a randomized trial in patients with SCD that compared two different doses of crizanlizumab and placebo, administered intravenously every four weeks over a year, vasoocclusive pain episodes decreased by about 50 percent (1.6 versus 3 events annually) in the higher-dose crizanlizumab group compared with placebo [9]. The benefit persisted regardless of the baseline frequency of painful events, SCD genotype, and concomitant hydroxyurea use. This agent, which is not yet clinically available, will likely be the first new disease-modifying agent for SCD since hydroxyurea was introduced as a therapy for SCD almost two decades ago. (See "Vasoocclusive pain management in sickle cell disease".)


Addition of idelalisib to bendamustine plus rituximab in CLL (March 2017)

The combination of idelalisib plus rituximab is one of our preferred treatments for patients with refractory or early relapsing chronic lymphocytic leukemia (CLL). In a multicenter phase III trial of over 400 patients with relapsed/refractory CLL, the addition of idelalisib to the combination of bendamustine plus rituximab (BR) improved progression-free and overall survival, with moderate increases in infection and other toxicities [10]. These results provide further support for the efficacy of idelalisib plus rituximab in relapsed/refractory CLL. We do not usually incorporate bendamustine since the contribution of this agent to the regimen's efficacy is not clear. (See "Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Idelalisib'.)

Long-term follow-up of imatinib in CML (March 2017)

Imatinib was the first tyrosine kinase inhibitor (TKI) that specifically targeted BCR-ABL1, the fusion protein that underlies chronic myeloid leukemia (CML). In an analysis of long-term outcomes from the landmark IRIS trial, 83 percent of patients with chronic phase CML treated with imatinib were alive at 10 years [11]. Serious adverse events were uncommon and most frequently occurred in the first year of treatment. These excellent outcomes and favorable toxicity profile support our recommendation to use a BCR-ABL1 TKI (eg, imatinib, dasatinib, or nilotinib) for initial treatment of chronic phase CML. (See "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'IRIS trial'.)

Ibrutinib and Pneumocystis pneumonia (December 2016)

The Bruton tyrosine kinase inhibitor ibrutinib has not clearly been associated with an increased risk of opportunistic infections, but cases have been reported. In a series of 96 patients receiving ibrutinib as the sole agent for chronic lymphocytic leukemia (CLL), five were reported to have Pneumocystis pneumonia [12]. All of the infections were grade ≤2 and resolved with oral trimethoprim-sulfamethoxazole. A limitation is that the diagnoses were made by polymerase chain reaction (PCR) of bronchoalveolar lavage fluid, which could represent a false positive in the setting of colonization with Pneumocystis. Nevertheless, clinicians should have a high index of suspicion for Pneumocystis pneumonia in patients receiving ibrutinib, and the diagnosis should be sought in those with compatible signs and symptoms. (See "Risk of infections in patients with chronic lymphocytic leukemia", section on 'Ibrutinib' and "Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Ibrutinib and idelalisib'.)

Ibrutinib in chronic lymphocytic leukemia with del(17p) (October 2016)

Patients with chronic lymphocytic leukemia (CLL) with del(17p) or a TP53 mutation have low response rates and high relapse rates following treatment with most standard therapies. Subset analyses of larger studies suggested that this difficult-to-treat group could attain better outcomes with the Bruton's tyrosine kinase inhibitor ibrutinib. This was confirmed in a multicenter, single-arm trial of ibrutinib in 144 patients with relapsed/refractory CLL with del(17p) that showed an overall response rate of 83 percent and estimated rates of progression-free and overall survival at two years of 63 and 75 percent, respectively [13]. These results support our preference for single agent ibrutinib as the initial therapy in most patients with CLL demonstrating del(17p) or a TP53 mutation. (See "Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Ibrutinib'.)


Molecular markers of prognosis following transplant in myelodysplastic syndromes (February 2017)

Although allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelodysplastic syndromes (MDS), controversy surrounds selection of candidates, given the associated risks. In a retrospective study of over 1500 patients who underwent HCT for MDS, those whose biopsies revealed TP53 mutations experienced shorter overall survival, regardless of whether they underwent myeloablative conditioning (MAC) or reduced intensity conditioning (RIC) [14]. In contrast, those with RAS pathway mutations experienced worsened survival only if they received RIC. This analysis suggests that molecular features may increasingly aid in selection of candidates for HCT and influence the choice of conditioning regimen in MDS. (See "Hematopoietic cell transplantation in myelodysplastic syndromes", section on 'Cytogenetic and molecular factors'.)

Palliative care during hematopoietic cell transplantation (February 2017)

For patients with serious life-threatening illness, comprehensive palliative care can be successfully integrated with disease-modifying treatment. The benefits of delivering palliative care alongside potentially curative treatment were shown in a randomized trial of inpatient palliative care consultation versus usual transplant care in 160 adults with hematologic malignancies undergoing autologous or allogeneic hematopoietic cell transplantation [15]. At two weeks posttransplant, the increase in depression, anxiety, and overall symptom burden was less in the intervention group, and the decrease in quality of life (QOL) was also smaller. Depression and QOL benefits persisted at three months. (See "Benefits, services, and models of subspecialty palliative care", section on 'Rationale for palliative care'.)

Association of vitiligo with hematopoietic stem cell transplantation (February 2017)

Previous reports suggested that recipients of hematopoietic stem cell transplantation (HSCT) have an increased risk of developing vitiligo. In a Korean nationwide population study including approximately 2700 HSCT recipients and 8200 controls, HSCT recipients had a threefold increased risk of developing vitiligo [16]. Risk factors included receipt of an allogeneic versus autologous graft and stem cells derived from the bone marrow rather than peripheral blood. Although the pathogenetic mechanisms underlying the development of vitiligo in HSCT recipients are unclear, they may include adoptive transfer of vitiligo from donor, immunosuppression associated with preparative regimens, or chronic graft-versus-host disease. Clinicians should counsel patients undergoing HSCT regarding the risk of vitiligo. (See "Vitiligo: Pathogenesis, clinical features, and diagnosis", section on 'Etiology'.)


PLASMIC score for TTP (March 2017)

Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening condition in which platelet microthrombi can cause organ injury and infarction. Most patients with TTP have severely reduced activity of the von Willebrand factor cleaving protease ADAMTS13, but results of ADAMTS13 testing may take days to receive. The PLASMIC score was developed to predict the likelihood of ADAMTS13 activity ≤10 percent in adults with suspected TTP. In three cohorts involving over 500 patients, a high PLASMIC score was predictive of ADAMTS13 ≤10 percent [17,18]. This score cannot be used to confirm or exclude the diagnosis of TTP, but it may be helpful when there is lack of clarity regarding the most likely diagnosis and/or the need to initiate TTP therapy. (See "Acquired TTP: Clinical manifestations and diagnosis", section on 'Diagnostic evaluation'.)

Aspirin for prevention of preeclampsia (February 2017)

Low-dose aspirin therapy during pregnancy reduces the occurrence of preeclampsia in high-risk women, but questions remain about optimum dosing and timing. In one recent meta-analysis, the optimum aspirin dose appeared to be 100 to 150 mg, with favorable effects limited to initiation before 16 weeks of gestation [19]. In another recent meta-analysis with a different design, aspirin was similarly effective whether initiated before or after 16 weeks of gestation; optimum dosing was not assessed [20]. For women at high risk of developing preeclampsia, we continue to suggest initiating aspirin 81 mg daily at the end of the first trimester because this dose is readily available and early initiation is both safe and effective. If aspirin is not initiated at this time, initiation after 16 weeks, but before symptoms develop, also appears to be effective. (See "Preeclampsia: Prevention", section on 'Meta-analysis'.)

Underdosing of direct oral anticoagulants (February 2017)

The oral direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors apixaban, edoxaban, and rivaroxaban (collectively called direct oral anticoagulants [DOACs]) have been available for several years. A real-world study of over 1500 patients with venous thromboembolism (VTE) who were treated with a DOAC found that dosing differed from the recommended product dosing in 20 to 50 percent of cases, depending on the agent [21]. These deviations (mostly underdosing) correlated with an increased frequency of VTE recurrence. Clinicians should familiarize themselves with prescribing information to avoid adverse outcomes. (See "Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects", section on 'Clinician familiarity with dosing'.)

Dabigatran combined with certain statins associated with increased risk of major bleeding (February 2017)

An analysis of health records of nearly 46,000 Canadian patients showed that older adults (age ≥66) with atrial fibrillation taking dabigatran who also received simvastatin or lovastatin had approximately a 50 percent greater risk of hospitalization for major hemorrhage relative to those who used other statins [22]. Although the mechanism for this interaction is uncertain, until additional information becomes available, it may be prudent to choose a statin other than lovastatin or simvastatin for older patients receiving dabigatran, and for those with an elevated risk for serious bleeding. (See "Statins: Actions, side effects, and administration", section on 'Drug interactions'.)

Anticoagulant thromboprophylaxis not warranted in nonmajor lower limb orthopedic surgery (January 2017)

Whether anticoagulation thromboprophylaxis is indicated for patients with lower leg immobilization from below knee casting or undergoing arthroscopy was evaluated in a randomized trial [23]. The rate of symptomatic venous thromboembolism (VTE) was low (<2 percent) and not affected by the administration of anticoagulant prophylaxis. Risk factors in addition to the surgery itself were present among the few patients who did develop thrombus. This trial supports the current recommendation that, for patients with lower leg immobilization due to below knee casting or arthroscopy who do not have additional risk factors for VTE, anticoagulant prophylaxis is not warranted. (See "Prevention of venous thromboembolic disease in surgical patients", section on 'Orthopedic surgery'.)

Syncope and pulmonary embolus (October 2016)

While pulmonary embolus (PE) has generally been considered to be a relatively rare cause of syncope, a recent study reported a 17 percent prevalence of PE among patients admitted to hospital with syncope, and a 25 percent prevalence among those without an alternative etiology for syncope [24]. Two-thirds of patients with syncope secondary to PE had thrombus located in the mainstem or lobar arteries, suggesting that syncope may indicate a high burden of thrombus. The study underscores the importance of syncope as a presenting manifestation of clinically significant PE among patients with syncope who are admitted to the hospital. The prevalence of diagnosed PE was lower (4 percent) when looking at all patients seen in the emergency department with syncope, although the total number of these patients who were assessed for PE was not reported. (See "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'History and examination'.)


Ibrutinib in marginal zone lymphoma (January 2017)

Treatment of nodal marginal zone lymphoma (MZL) has been based on retrospective studies and extrapolation from trials in follicular lymphoma. In preliminary results of an open-label, single arm phase 2 trial, half of patients with relapsed MZL after anti-CD20-based treatment responded to ibrutinib [25]. These higher-than-expected response rates led to accelerated approval by the US Food and Drug Administration for use of ibrutinib in this MZL population. Given these findings, ibrutinib is an additional option for patients with MZL who have relapsed after anti-CD20-based treatment, though further study is needed to determine if it will improve survival. (See "Treatment of marginal zone (MALT) lymphoma", section on 'Treatment'.)

Obinutuzumab-based regimens for previously untreated follicular lymphoma (December 2016)

Preliminary results from an international, open-label, randomized phase III trial comparing an obinutuzumab-based induction and maintenance strategy versus a rituximab-based strategy in 1202 patients with previously untreated advanced- stage follicular lymphoma have been presented in abstract form [26]. At a median follow-up of 35 months, the obinutuzumab-based strategy resulted in deeper responses and superior progression-free survival. It is not known whether this will translate into an overall survival benefit with longer follow-up. While we generally prefer rituximab-based regimens, these results suggest that obinutuzumab-based regimens are an acceptable alternative for the initial treatment of advanced-stage follicular lymphoma. (See "Initial treatment of advanced stage (III/IV) follicular lymphoma", section on 'Choice of anti-CD20 antibody'.)


Early versus delayed transplant for multiple myeloma (April 2017)

Autologous hematopoietic cell transplantation (HCT) extends the survival of, though does not cure, patients with multiple myeloma. Timing for HCT was evaluated in a trial of 700 adults ≤65 years of age who had completed induction therapy with bortezomib, lenalidomide, and dexamethasone (VRD) [27]. Early transplant, following induction with VRD, was compared with delayed transplant (consolidation VRD and transplant at the time of first relapse). Approximately 80 percent of patients assigned to further VRD underwent HCT at relapse. With a median follow-up of 44 months, early HCT resulted in a longer progression-free survival, but no difference in overall survival. We take patient preference, age, genetic risk profile, and logistic factors into account to individualize the timing of HCT. (See "Autologous hematopoietic cell transplantation in multiple myeloma", section on 'Timing of first HCT'.)

Chemotherapy for C3 glomerulopathy with monoclonal gammopathy (March 2017)

C3 glomerulopathy with monoclonal gammopathy is a form of monoclonal gammopathy of renal significance (MGRS), a group of kidney disorders caused by a monoclonal immunoglobulin that is secreted by a nonmalignant or premalignant B cell or plasma cell clone. A retrospective analysis compared renal outcomes among 50 patients with C3 glomerulopathy with monoclonal gammopathy who were treated with or without chemotherapy directed against the underlying plasma or B cell clone [28]. Treatment with clone-directed chemotherapy was associated with a higher rate of renal response and improved renal survival at a median of 24 months. Importantly, renal survival was significantly higher among patients who achieved a hematologic response with chemotherapy. We typically treat patients who have C3 glomerulopathy with monoclonal gammopathy using chemotherapy based upon the isotype of the circulating monoclonal protein detected in the serum or urine. (See "Diagnosis and treatment of monoclonal gammopathy of renal significance", section on 'Patients with C3 glomerulopathy with monoclonal gammopathy'.)

Bortezomib, lenalidomide, dexamethasone for previously untreated multiple myeloma (December 2016)

Until now, published data regarding bortezomib, lenalidomide, and dexamethasone (VRd) in previously untreated multiple myeloma (MM) was limited to phase 2 trials. In a multicenter phase 3 trial (SWOG S0777), 525 patients with previously untreated MM were randomly assigned to receive six months of induction therapy with either VRd or Rd, each followed by Rd maintenance until progression or unacceptable toxicity [29]. VRd resulted in higher response rates and improved both progression-free and overall survival. This supports our preference for VRd as the initial treatment of most patients with standard-risk MM. Given that VRd is associated with greater toxicity, Rd is an acceptable alternative for frail adults, especially those with preexisting neuropathy, and patients age 75 years or older who are expected to have higher rates of toxicity with VRd. (See "Selection of initial chemotherapy for symptomatic multiple myeloma", section on 'Bortezomib, lenalidomide, dexamethasone (VRd)'.)


Screening donated blood for babesiosis in the United States (December 2016)

Naturally occurring Babesia microti infection within the United States is regionally distributed, with high-risk areas located in the Northeast and upper Midwest. In an analysis of almost 90,000 blood donations from four states in these regions, 335 (0.38 percent) were found to be positive for B. microti using a DNA-based or antibody-based test [30]. Screening of donated units was found to be effective in preventing transmission. Testing blood donations for B. microti is not mandatory in the US, but many units collected in high-risk regions are being screened. (See "Blood donor screening: Laboratory testing", section on 'Babesia microti'.)

Transfusion outcomes with "fresh" versus "old" blood (November 2016)

The INFORM trial (Informing Fresh versus Old Red Cell Management) is the largest trial to compare clinical outcomes with "fresh" versus "old" blood [31]. In INFORM, over 20,000 hospitalized adults who required transfusion were randomly assigned to receive "old" red blood cells (RBCs; stored for a mean of 24 days) or "fresh" RBCs (stored for a mean of 13 days). There were no differences in mortality or hospital length of stay. Smaller trials in adults, children, and neonates have also concluded that outcomes are unaffected by RBC storage duration. (See "Red blood cell transfusion in adults: Storage, specialized modifications, and infusion parameters", section on 'Clinical relevance of storage time'.)

Updated guideline and meta-analysis on hemoglobin thresholds for blood transfusion (November 2016)

An updated systematic review and meta-analysis of randomized trials involving over 12,000 patients has provided more support for the use of a restrictive transfusion strategy (giving less blood, transfusing at a lower hemoglobin level, typically 7 to 8 g/dL) for most hemodynamically stable medical and surgical patients who are not actively bleeding or symptomatic from anemia [32]. An updated 2016 guideline from the AABB (an international organization) also supports the use of restrictive thresholds [33]. The major exception is patients with acute coronary syndromes (ACS), for whom data from large randomized trials are not available and for whom pilot trials suggest a more liberal threshold may be associated with better outcomes. We continue to use an individualized approach to transfusion in patients with ACS. (See "Indications and hemoglobin thresholds for red blood cell transfusion in the adult", section on 'Society guidelines'.)


Subcutaneous C1 inhibitor for hereditary angioedema (April 2017)

Patients with hereditary angioedema (C1 inhibitor deficiency) suffer attacks of angioedema affecting the skin, gastrointestinal tract, and airway, which can be prevented with intravenous infusions of C1 inhibitor, typically given twice weekly. Subcutaneous administration would significantly facilitate self-treatment. In a randomized multicenter trial of 90 children and adults, participants injected a subcutaneous formulation of C1 inhibitor or placebo twice weekly for 16 weeks [34]. Therapy was well tolerated and attack rates were reduced by approximately 90 percent relative to placebo. This preparation is not currently available outside of clinical trials, although approval in the future is anticipated. (See "Hereditary angioedema: General care and long-term prophylaxis", section on 'Subcutaneous C1 inhibitor'.)

Autoimmune hemolytic anemia after recovery from babesiosis (March 2017)

Babesiosis is known to cause hemolysis from direct parasite-mediated lysis of red blood cells in the circulation. A new association of Babesia infection with autoimmune (autoantibody-mediated) hemolytic anemia (AIHA) has been reported [35]. In a series of 86 patients treated for Babesia, 7 percent developed this complication. AIHA was diagnosed two to four weeks after recovery from the infection and was restricted to individuals who were asplenic due to a prior splenectomy. (See "Warm autoimmune hemolytic anemia: Clinical features and diagnosis", section on 'Underlying causes'.)

E. coli O157:H7 outbreak associated with soy nut butter (March 2017)

Escherichia coli O157:H7, which causes bloody diarrhea and is associated with the hemolytic-uremic syndrome, is typically transmitted through contaminated beef products and produce, but other foods have also been implicated in outbreaks. In the United States, a particular brand of soy nut butter (I.M. Healthy) has been linked to a multistate E. coli O157:H7 outbreak that has affected mainly children [36]. Although the soy nut butter products have been recalled, individuals should be advised to avoid and discard any remaining product, and the possibility of E. coli O157:H7 infection should be considered in exposed patients with diarrheal illnesses. Details on the outbreak can be found on the Centers for Disease Control and Prevention website. (See "Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)", section on 'Other foods'.)

Masitinib in indolent and smoldering systemic mastocytosis (February 2017)

There are limited treatment options for indolent and smoldering systemic mastocytosis (ISM and SSM, respectively). Masitinib is a tyrosine kinase with activity against at least three mast cell signaling molecules. In a phase III trial of 135 severely symptomatic patients with ISM or SSM, oral masitinib reduced symptoms, tryptase levels, and urticaria pigmentosa lesions compared with placebo, although it was associated with side effects requiring discontinuation in 24 percent [37]. The drug is under regulatory review, and further data about the safety and efficacy are needed before its use can be recommended. (See "Systemic mastocytosis: Management and prognosis", section on 'Clinical trials'.)

Updated MASCC/ESMO guidelines for nausea and emesis related to cancer treatment (October 2016)

Updated guidelines for prevention and management of cancer therapy-associated nausea and vomiting are available from the Multinational Association of Supportive Care in Cancer and the European Society of Medical Oncology (table 2), the consensus panel also provides guidance on the use of prophylactic antiemetics in patients undergoing radiation therapy. (See "Prevention and treatment of chemotherapy-induced nausea and vomiting in adults", section on 'Recommendations for specific groups'.)

Thrombotic microangiopathy from interferon (October 2016)

Drug-induced thrombotic microangiopathy (DITMA) has been described with a number of chemotherapeutic, immunosuppressive, and other drugs. Unlike thrombotic thrombocytopenic purpura (TTP), DITMA is not associated with severely reduced ADAMTS13 activity, and the principal treatment is drug discontinuation rather than plasma exchange. A new report has provided strong evidence for interferon as a cause of TMA [39]. Patients receiving interferon who develop signs of a TMA should have the drug discontinued promptly before organ failure develops. (See "Drug-induced thrombotic microangiopathy", section on 'Immunosuppressive agents'.)

Use of UpToDate is subject to the Subscription and License Agreement.


  1. Platzbecker U, Avvisati G, Cicconi L, et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol 2017; 35:605.
  2. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 2017; 376:836.
  3. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129:424.
  4. Liem RI, Chan C, Vu TT, et al. Association among sickle cell trait, fitness, and cardiovascular risk factors in CARDIA. Blood 2017; 129:723.
  5. Bello NA, Hyacinth HI, Roetker NS, et al. Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function. Blood 2017; 129:799.
  6. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med 2017; 376:848.
  7. Lacy ME, Wellenius GA, Sumner AE, et al. Association of Sickle Cell Trait With Hemoglobin A1c in African Americans. JAMA 2017; 317:507.
  8. Chaturvedi S, Ghafuri DL, Glassberg J, et al. Rapidly progressive acute chest syndrome in individuals with sickle cell anemia: a distinct acute chest syndrome phenotype. Am J Hematol 2016; 91:1185.
  9. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med 2017; 376:429.
  10. Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2017; 18:297.
  11. Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 2017; 376:917.
  12. Ahn IE, Jerussi T, Farooqui M, et al. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood 2016; 128:1940.
  13. O'Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016; 17:1409.
  14. Lindsley RC, Saber W, Mar BG, et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 2017; 376:536.
  15. El-Jawahri A, LeBlanc T, VanDusen H, et al. Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA 2016; 316:2094.
  16. Bae JM, Choi KH, Jung HM, et al. Subsequent vitiligo after hematopoietic stem cell transplantation: A nationwide population-based cohort study from Korea. J Am Acad Dermatol 2017; 76:459.
  17. Jamme M, Rondeau E. The PLASMIC score for thrombotic thrombocytopenic purpura. Lancet Haematol 2017; 4:e148.
  18. Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol 2017; 4:e157.
  19. Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216:110.
  20. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017; 216:121.
  21. Trujillo-Santos J, Di Micco P, Dentali F, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost 2017; 117:382.
  22. Antoniou T, Macdonald EM, Zhan Y et al. Association between statin use. CMAJ 2017; 189.
  23. van Adrichem RA, Nemeth B, Algra A, et al. Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting. N Engl J Med 2017; 376:515.
  24. Prandoni P, Lensing AW, Prins MH, et al. Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope. N Engl J Med 2016; 375:1524.
  25. Noy A, de Vos S, Thieblemont C, et al. Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study (abstract 1213). Blood 2016.
  26. Marcus RE, Davies AJ, Ando K, et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized Phase III GALLIUM study (abstract 6). Blood 2016.
  27. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 2017; 376:1311.
  28. Chauvet S, Frémeaux-Bacchi V, Petitprez F, et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 2017; 129:1437.
  29. Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017; 389:519.
  30. Moritz ED, Winton CS, Tonnetti L, et al. Screening for Babesia microti in the U.S. Blood Supply. N Engl J Med 2016; 375:2236.
  31. Heddle NM, Cook RJ, Arnold DM, et al. Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. N Engl J Med 2016; 375:1937.
  32. Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2016; 10:CD002042.
  33. Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA 2016; 316:2025.
  34. Longhurst H, Cicardi M, Craig T, et al. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med 2017; 376:1131.
  35. Woolley AE, Montgomery MW, Savage WJ, et al. Post-Babesiosis Warm Autoimmune Hemolytic Anemia. N Engl J Med 2017; 376:939.
  36. Multistate Outbreak of Shiga toxin-producing Escherichia coli O157:H7 Infections Linked to I.M. Healthy Brand SoyNut Butter (Accessed on March 06, 2017).
  37. Lortholary O, Chandesris MO, Bulai Livideanu C, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet 2017; 389:612.
  38. Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27:v119.
  39. Kavanagh D, McGlasson S, Jury A, et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood 2016; 128:2824.
Topic 8359 Version 7133.0

Topic Outline



All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.